Paragard IUD lawsuit update

Verified snapshot

The facts that anchor this dossier

Paragard MDL 2974 focuses on alleged breakage during removal. FDA labeling acknowledges reported breakage in embedded devices, but the docket still requires case-specific proof and has no public universal settlement program.

Federal proceeding

MDL 2974

Coordinated in the Northern District of Georgia before Judge Leigh Martin May.

Pending actions

4,111

JPML count as of July 1, 2026; 4,409 historical actions.

Central allegation

Breakage during removal

JPML described allegations of breakage leading to retained fragments, surgery, pain and other claimed injuries; defendants contest liability.

FDA label

Breakage of an embedded Paragard has been reported

The 2024 label also says partial embedment can make removal difficult and surgical removal may be necessary.

Settlement status

No universal public program identified

The official court pages reviewed list case management, bellwether scheduling and dispositive rulings, not a courtwide payout matrix.

Documented chronology

How the litigation reached this point

The narrow center of the federal litigation

Paragard is a T-shaped copper intrauterine contraceptive. When it centralized the cases, the JPML said the actions shared allegations that the device had a propensity to break during removal, potentially leading to surgery to retrieve a fragment, pain, infertility and other complications. The Northern District of Georgia's case summary uses similarly careful language: these are plaintiffs' allegations, not established facts for every removal.

The MDL is narrower than every problem that can occur with an IUD. Insertion perforation, expulsion, pregnancy, bleeding, embedment and removal breakage are medically and factually different events. A page that groups them all as “Paragard breakage” can misstate the case. The operative note, intact or fragmented device, imaging and follow-up procedure usually show which event actually occurred.

What FDA labeling confirms

The 2024 FDA-approved prescribing information says partial penetration or embedment in the uterine muscle can make removal difficult, that surgical removal may be necessary, and that breakage of an embedded Paragard during non-surgical removal has been reported. It instructs clinicians to remove the device by applying steady traction to the strings and says that if it cannot be removed with gentle traction, the location should be determined and removal may require hysteroscopy or another procedure.

The label also separates perforation from breakage. It reports a 0.2% incidence of perforation during or after insertion in clinical trials—13 of 5,344—and warns that delayed detection can allow migration and injury to adjacent structures. That trial figure should not be repurposed as a breakage rate. The approved label does not provide a population incidence for removal breakage, and adverse-event reports cannot supply one because reporting is incomplete and lacks a known denominator.

How to understand adverse-event research

A 2023 pharmacovigilance study counted breakage reports in FDA's adverse-event reporting system through February 2022 and found breakage was disproportionately represented among copper-IUD reports compared with hormonal-IUD reports. The authors explicitly stated that the true prevalence could not be calculated from the dataset. This is an important signal-generating result, not a rate showing how often Paragard breaks in ordinary use.

Case reports and clinician surveys show that retained or fragmented IUDs can be managed with imaging, office retrieval or hysteroscopy depending on location and circumstances. They cannot establish that a design defect caused a specific event. Difficult removal can involve missing strings, embedment, anatomical factors and duration of use. The clinical question—how to retrieve a device safely—is related to but distinct from the legal questions of defect, warning, causation and damages.

The MDL's procedural path

After centralization in December 2020, the court organized master pleadings, service, fact sheets, document production and a bellwether pool. In February 2025 it entered a 57-page order applying different states' statutes of limitation and repose to specified cases. That order is a practical warning against national one-size-fits-all deadline advice: the governing rule can depend on residence, insertion, removal, discovery of injury and the claims pleaded.

The September 2025 scheduling order laid out expert discovery, Rule 702 motions, dispositive motions and trial preparation for three selected cases, with listed dates through May 2026. The court's public MDL pages had not posted a newer generally applicable scheduling order when this dossier was verified. Because schedules can change through docket entries not mirrored on a summary page, readers should not infer from a planned date alone that a trial occurred or produced a verdict.

What a complete personal record looks like

Start with the insertion record and device identity, then the removal note. Was the device embedded? Did a transverse arm separate? Was the fragment visualized on ultrasound or X-ray? Did office retrieval succeed, or was hysteroscopy, laparoscopy or another procedure used? Pathology, operative findings, symptoms and follow-up help distinguish a retained fragment from unrelated pelvic conditions.

Preserve the actual device only through appropriate clinical and legal channels; patients should not interfere with medical handling. A break is not by itself a guaranteed lawsuit or settlement. The timeline, injury, causation, responsible entity and state law still matter. As of July 10, 2026, the reviewed official court materials do not announce a universal Paragard settlement, public claim deadline or fixed payout schedule.

Reader questions

Frequently asked questions